Get started
Author

Emanuela Miraglio

Observed names: E. Miraglio, E. miraglio
OpenAlex ID: A5020090430
Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy
2016 · Cristiana Lo Nigro, Vincenzo Ricci, et al. · World Journal of Gastroenterology · 61
PDF
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
2017 · Federica Marmorino, Lisa Salvatore, et al. · British Journal of Cancer · 40
PDF
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study
2017 · M.E. Cazzaniga, M. Airoldi, et al. · The Breast · 22
Eribulin in Advanced Breast Cancer: Safety, Efficacy and New Perspectives
2017 · Ornella Garrone, Emanuela Miraglio, et al. · Future Oncology · 21
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP” trial by the Gruppo Oncologico Nord Ovest (GONO).
2013 · Gianluca Masi, Fotios Loupakis, et al. · Journal of Clinical Oncology · 20
A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
2015 · Ornella Garrone, Gianfilippo Bertelli, et al. · PubMed · 4
Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.
2014 · Lisa Salvatore, Fotios Loupakis, et al. · Journal of Clinical Oncology · 3
Bevacizumab Beyond Progression in Metastatic Colorectal Cancer Patients Receiving a First-Line Treatment Containing Bevacizumab: Update of Bebyp Trial by Gono
2013 · Lisa Salvatore, Gianluca Masi, et al. · Annals of Oncology · 3
PDF
Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
2016 · E. Fea, P. Vanella, et al. · Annals of Oncology · 2
Breast cancer with synchronous and metachronous metastatic spreading. A single institution experience
2016 · A.M. Vandone, O. Garrone, et al. · Annals of Oncology · 1
PDF
Mismatch repair protein expression in lynch-associated neoplasms: analysis of 173 patients with endometrial cancer
2026 · Marinella Destefanis, Elena Olearo, et al. · International Journal of Gynecological Cancer
Unlocking biomarkers' prognostic, predictive and preventive power: the case manager’s role in personalized gynecologic oncology pathways
2026 · Marinella Destefanis, Carmelo Calidona, et al. · International Journal of Gynecological Cancer
Mirvetuximab in proc FRα-high: A promising therapeutic strategy
2026 · Marinella Destefanis, Elena Olearo, et al. · International Journal of Gynecological Cancer
POLE-mutated endometrial cancer: from genomics to clinical reality
2026 · Marinella Destefanis, Carmelo Calidona, et al. · International Journal of Gynecological Cancer
ESR1 mutation: A potential preventive biomarker in endometrial cancer?
2026 · Marinella Destefanis, Elena Olearo, et al. · International Journal of Gynecological Cancer
The crucial role of the geneticist in gynecologic oncology
2026 · Marinella Destefanis, Carmelo Calidona, et al. · International Journal of Gynecological Cancer
Cervical Necrosis After Radical Chemoradiation For Cervical Cancer And Correlated Risk Factors In A Mono-Institutional Series
2025 · Francesco Olivero, Stefania Martini, et al. · International Journal of Gynecological Cancer
PDF
From Tumors To Genetic Syndromes Through HRD And Other HRR Genes In Ovarian Cancers
2025 · Marinella Destefanis, Elena Olearo, et al. · International Journal of Gynecological Cancer
Nab-paclitaxel in clinical practice: data from the MANTEL study
2017 · P. Vanella, O. Garrone, et al. · Annals of Oncology
Nab-paclitaxel in clinical practice: Preliminary data from the mantel study.
2017 · Ornella Garrone, Chiara Saggia, et al. · Journal of Clinical Oncology
Nab-paclitaxel in clinical practice: preliminary results from MANTEL Study
2016 · P. Vanella, O. Garrone, et al. · Annals of Oncology
Maintenance hormonal therapy (MHT) in metastatic breast cancer (MBC) patients treated with first-line chemotherapy: retrospective analysis of the impact on progression-free survival (PFS) and overall survival (OS) in a “real life” setting
2016 · O. Garrone, M. Di Maio, et al. · Annals of Oncology
PDF
Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
2016 · F. Marmorino, C. Cremolini, et al. · Annals of Oncology
PDF
PD-004 Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study
2016 · F. Marmorino, C. Cremolini, et al. · Annals of Oncology
PDF
Predictive role of clinical benefit (CB) at 1st line on the outcome of subsequent lines in metastatic breast cancer (MBC) patients: analysis of a “real life” population.
2016 · Ornella Garrone, Massimo Di Maio, et al. · Journal of Clinical Oncology
Works count: 35
Citation count: 177
H-index: 5
I10-index: 5
Year
Topic
Type